---
title: "Legionnaires' disease in immunocompromised patients: atypical presentation and non-pneumophila species"
source_url: https://legionella.io/articles/legionnaires-disease-in-immunocompromised-patients/
canonical_url: https://legionella.io/articles/legionnaires-disease-in-immunocompromised-patients/
pillar: "Legionella Basics & Science"
summary: "Why Legionella hits transplant and biologic-treated patients harder, the non-pneumophila species the urine test misses, and what it means for water safety"
primary_keyword: "Legionnaires disease immunocompromised"
date_published: 2026-06-27
date_reviewed: 2026-06-27
author: "Legionella.io editorial team (REMOTE TECH LTD)"
reviewed_against: "HSE L8 and HSG274 guidance"
region: "United Kingdom"
license: "CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Quote, adapt or republish with attribution to REMOTE TECH LTD and a link to source_url."
license_url: https://creativecommons.org/licenses/by/4.0/
---

# Legionnaires' disease in immunocompromised patients: atypical presentation and non-pneumophila species

In a transplant recipient or someone on high-dose steroids, Legionnaires' disease often looks different and behaves worse: it moves faster, runs more severe, can reach beyond the lung, and is frequently caused by a species the standard urine test cannot see.

That last point is the one that catches clinical teams out. A negative urinary antigen result in a severely immunosuppressed patient does not rule Legionella out, and in this group, ruling it out wrongly is expensive in a way it rarely is for a previously healthy host.

## Why immunosuppression changes the disease, not just the odds

Legionella is an intracellular pathogen. It is taken up by alveolar macrophages and survives inside them, and the host depends heavily on cell-mediated immunity, competent macrophages and a working T-cell response, to bring the infection under control. Antibody and neutrophil defences matter, but they are not the main line of defence here.

That mechanism explains who is most affected. The therapies that most sharply raise risk are the ones that blunt cell-mediated immunity: solid-organ and haematopoietic stem-cell transplantation, high-dose or prolonged corticosteroids, calcineurin inhibitors, and biologic agents, TNF-alpha inhibitors in particular have a recognised association with intracellular infections. Add the receipt of immunosuppression in a hospital with a colonised water system, and you have the combination that drives most healthcare-associated cases [1][4].

Severity tracks the same logic. Reported case-fatality is substantially higher in immunocompromised patients than in otherwise healthy ones, and disease can progress to respiratory failure quickly [2]. The clinical lesson is one of threshold rather than picture: in this population, suspect Legionella earlier and test more completely, because the cost of a late diagnosis is high.

## The species the urine test misses

Most community Legionnaires' disease is *Legionella pneumophila* serogroup 1, and most diagnostic systems are tuned to it. The urinary antigen test, fast, cheap, and the workhorse of routine practice, detects predominantly *L. pneumophila* serogroup 1 and performs poorly against other serogroups and against non-pneumophila species [1].

In immunocompromised patients that bias matters far more, because this group carries a disproportionate share of the non-pneumophila disease. Two species recur in the transplant and haematology literature:

- ***Legionella micdadei***, historically the "Pittsburgh pneumonia agent", is classically described in immunosuppressed patients and is associated with cavitating pneumonia and lung abscess.
- ***Legionella longbeachae*** is reported as a more significant cause of disease in some regions, and is associated with soil and potting compost rather than building water systems [3], relevant when taking an exposure history, and a reminder that not every case traces back to a tap.

Others, *L. bozemanae*, *L. dumoffii*, *L. feeleyi* and further species, appear sporadically, again skewed toward the immunosuppressed. The practical consequence is the same for all of them: a urinary antigen test that comes back negative has told you very little. Confirming or excluding Legionella in a severely immunosuppressed patient with pneumonia leans on culture and, where available, lower respiratory PCR.

## A detection map you can sketch

The relationship between host, organism, presentation and test is easiest to hold as a single branching map. Picture four columns, left to right, with arrows running across them.

**Column 1, host.** Two boxes: *immunocompetent* and *severely immunosuppressed* (transplant, biologics, high-dose steroids).

**Column 2, likely species.** From the immunocompetent box, a thick arrow to *L. pneumophila serogroup 1*. From the immunosuppressed box, that same arrow is present **plus** a fan of additional arrows to *other L. pneumophila serogroups* and to *non-pneumophila species* (*L. micdadei*, *L. longbeachae* and others). The fan is the whole point: the species spectrum widens with immunosuppression.

**Column 3, presentation.** From serogroup 1, an arrow to *typical lobar/severe pneumonia*. From the non-pneumophila fan, arrows to *cavitating pneumonia / abscess* and a thin, dashed arrow to *rare extrapulmonary sites* (wound, prosthetic, endocardial, septic-arthritic), almost all of which are documented in immunosuppressed hosts.

**Column 4, what each test sees.** Draw a horizontal "detection bar" across the species column. The *urinary antigen test* bar covers only the *L. pneumophila serogroup 1* arrow, everything in the fan passes underneath it undetected [1]. The *culture on BCYE agar* bar stretches across the entire column: all species, all serogroups, at the cost of time and a good lower-respiratory specimen [1]. A *PCR* bar sits between the two, broader than the antigen test but dependent on assay design and sample quality.

Sketched out, the diagram makes the failure mode obvious. The faster the test, the narrower its coverage, and the patients with the widest species spectrum are exactly the ones for whom the narrow test is used first.

## Atypical and extrapulmonary disease

Beyond cavitation, immunosuppressed patients account for most of the rare extrapulmonary Legionella reports: wound and soft-tissue infection, prosthetic-joint and native-valve involvement, and occasional disseminated disease. These are uncommon enough that no clinician should expect them routinely, but common enough in this group that an unexplained culture-negative collection in a transplant patient is worth a second thought and a conversation with microbiology.

Extra-respiratory features can also accompany the pneumonia itself, confusion, gastrointestinal symptoms, hyponatraemia and deranged liver function are described, and may be more prominent when the host response is altered. None of these is specific, and none replaces a microbiological diagnosis.

Choice of empirical and definitive therapy is a clinical decision for the treating team and the local microbiology service, weighing the patient's drug interactions and immunosuppression; it sits outside the scope of this article, and patients should be guided by their own clinicians and NHS advice.

A note on the youngest patients: Legionnaires' disease is rare in children, but is reported in immunocompromised paediatric and neonatal cases, sometimes linked to hospital water or birthing-water exposure. That is a specialist area and is flagged here rather than covered, refer to paediatric infectious-disease and IPC teams.

## What this means for water safety in augmented care

Clinical vigilance is only half the response. Where the most susceptible patients are nursed, transplant, haemato-oncology, intensive care and other augmented-care areas, the water system is a controllable source, and the bar is higher than for a general ward. NHS England's healthcare water-safety guidance, HTM 04-01, sets out the augmented-care thinking: closer monitoring, water-safety-group oversight, and point-of-use measures such as terminal filtration on outlets serving the highest-risk patients [4]. The risk-assessment frame for all of this is BS 8580-1, applied to the specific patient group and building, with HSG274 informing the engineering controls [5].

The species point feeds back into surveillance. Because routine clinical testing is weighted toward *L. pneumophila* serogroup 1, a water system can carry other species or serogroups that rarely show up in urine-antigen-led diagnosis. Where there is a cluster, or an unexplained case in augmented care, environmental sampling and culture, and matching clinical and environmental isolates, does work the antigen test cannot [1][6].

This is general clinical and engineering background, not a protocol. Decisions about an individual patient belong to the treating clinicians, and decisions about a specific water system belong to a competent person's site-specific risk assessment under the relevant standards. Nothing here is a substitute for either.

## FAQ

### Does a negative urinary antigen test rule out Legionnaires' disease in an immunosuppressed patient?

No. The urinary antigen test detects mainly *L. pneumophila* serogroup 1 and misses most other serogroups and non-pneumophila species, and immunosuppressed patients carry a disproportionate share of exactly those organisms. A negative result in this group should prompt lower-respiratory culture on BCYE agar and, where available, PCR, rather than closing the question.

### Which Legionella species matter most in transplant and biologic-treated patients?

*L. pneumophila* serogroup 1 still features, but *L. micdadei* (classically the immunosuppressed-host species, linked to cavitating pneumonia) and *L. longbeachae* recur in this population, alongside sporadic *L. bozemanae*, *L. dumoffii* and others. The shared feature is that the standard urine test does not detect them.

### Can Legionella infection appear outside the lungs?

It can, though it is uncommon. Most reported extrapulmonary Legionella, wound, soft-tissue, prosthetic-joint and endocardial infection, and rare disseminated disease, occurs in immunosuppressed patients. An unexplained, culture-negative infection in a transplant recipient can justify discussing Legionella culture with microbiology.

### Is the water-safety regime for these patients different from a general ward?

Yes. Areas nursing the most susceptible patients are treated as augmented care, with closer monitoring, water-safety-group oversight and point-of-use controls such as terminal filtration, set out in HTM 04-01 and assessed through BS 8580-1 and HSG274. The control target is tighter precisely because the host defences are weaker.

## What to do next

If you sit on a water safety group or run an augmented-care area, take one action this week: check that your local pneumonia and IPC pathways tell clinicians to send lower-respiratory culture, not just a urinary antigen, for severely immunosuppressed patients with pneumonia. If the pathway stops at the urine test, the non-pneumophila cases in your highest-risk patients are the ones it will quietly miss.

## Related reading

- [Legionella in healthcare: HTM 04-01 and NHS guidance](https://legionella.io/articles/legionella-in-healthcare-htm-04-01-and-nhs-guidance/)
- [Point-of-use water filters in high-risk settings](https://legionella.io/articles/point-of-use-water-filters-for-legionella-in-high-risk-and-augmented-care-settings/)
- [Diagnosing Legionnaires' disease beyond the urinary antigen test](https://legionella.io/articles/diagnosing-legionnaires-disease-beyond-the-urinary-antigen-test/)
- [Legionella species and serogroups beyond L. pneumophila](https://legionella.io/articles/legionella-species-and-serogroups-beyond-l-pneumophila/)
- [BS 8580-1: what a good risk assessment includes](https://legionella.io/articles/bs-8580-1-what-a-good-legionella-risk-assessment-should-include/)

## Sources

[1] CDC, "Legionella (Legionnaires' Disease and Pontiac Fever): Diagnostic Testing". https://www.cdc.gov/legionella/clinicians/diagnostic-testing.html
[2] UKHSA, "Legionnaires' disease: guidance, data and analysis". https://www.gov.uk/government/collections/legionnaires-disease-guidance-data-and-analysis
[3] WHO, "Legionellosis fact sheet". https://www.who.int/news-room/fact-sheets/detail/legionellosis
[4] NHS England, "Health Technical Memorandum 04-01: Safe water in healthcare premises". https://www.england.nhs.uk/publication/safe-water-in-healthcare-premises-htm-04-01/
[5] HSE, HSG274 Part 2 (2024), “Operation and inspection of hot and cold water systems”, p.70. https://www.hse.gov.uk/pubns/books/hsg274.htm
[6] ECDC, "Legionnaires' disease". https://www.ecdc.europa.eu/en/legionnaires-disease